Navigation

ExploreAnalysisInvestor RelationsAI AssistantCompareScreener
LoginSign Up FreeSign Up

© 2026 MarketCI. All rights reserved.

HelpPricingPrivacyTerms
IN

INDV

Market Closed

Indivior Pharmaceuticals Inc

NASDAQHealthcareDrug Manufacturers - Specialty & Generic
US
833 employees
CEO: Joseph J. Ciaffoni
Founded: 2014
$34.77
+$0.00(+NaN%)
Market Cap
4.34B
Beta
1.11
52W Range
N/A
Dividend Yield
0.00%
OverviewForecastsFundamentalMarket SentimentValuationOwnership
OverviewForecastsFundamentalMarket SentimentValuationOwnership
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Indivior’s current price slightly exceeds the PERT-weighted fair value, indicating mild overvaluation amid high analyst targets and P/E ratios skewed above other metrics. Strong leverage and efficiency contrast with poor profitability, heightening operational risk. Monte Carlo results reveal 100% downside risk, evidencing significant price volatility.
Enhanced Football Field Analysis
Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore INDV

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

INDV in the Healthcare

Mid Cap
Healthcare

Browse sector stocks →

Drug Manufacturers - Specialty & Generic

Browse industry stocks →